Vertex Pharmaceuticals VRTX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Vertex Pharmaceuticals (VRTX) Business Model and Operations Summary
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Key Insights
Vertex Pharmaceuticals (VRTX) Core Market Data and Business Metrics
Latest Closing Price
$484.74Market Cap
$124.36 BillionPrice-Earnings Ratio
-233.05Total Outstanding Shares
256.79 Million SharesTotal Employees
6,100Dividend
No dividendIPO Date
July 31, 1991SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
50 Northern Avenue, Boston, MA, 02210
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-5.76 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-3.77 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-1.49 Billion |
| Exchange Gains/Losses | $-42.60 Million |
| Net Cash Flow From Financing Activities | $-1.49 Billion |
| Net Cash Flow From Investing Activities | $-3.77 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit | $784.10 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-535.60 Million |
| Benefits Costs and Expenses | $10.77 Billion |
| Costs And Expenses | $11.25 Billion |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $142.10 Million |
| Other Comprehensive Income/Loss | $-393.50 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-393.50 Million |
| Comprehensive Income/Loss Attributable To Parent | $-393.50 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $413 Million |
| Commitments and Contingencies | $0 |
| Current Assets | $9.60 Billion |
| Inventory | $1.21 Billion |
| Intangible Assets | $825.90 Million |
| Other Current Assets | $8.29 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||